MOA Life Plus Co (XKRX:142760) FCF Margin % : 460.86% (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is MOA Life Plus Co FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. MOA Life Plus Co's Free Cash Flow for the three months ended in Jun. 2024 was ₩18,224.22 Mil. MOA Life Plus Co's Revenue for the three months ended in Jun. 2024 was ₩3,954.43 Mil. Therefore, MOA Life Plus Co's FCF Margin % for the quarter that ended in Jun. 2024 was 460.86%.

As of today, MOA Life Plus Co's current FCF Yield % is -0.42%.

The historical rank and industry rank for MOA Life Plus Co's FCF Margin % or its related term are showing as below:

XKRX:142760' s FCF Margin % Range Over the Past 10 Years
Min: -407.25 Med: -68.61 Max: 31.77
Current: 0.89

During the past 10 years, the highest FCF Margin % of MOA Life Plus Co was 31.77%. The lowest was -407.25%. And the median was -68.61%.

XKRX:142760's FCF Margin % is ranked better than
79.71% of 1050 companies
in the Biotechnology industry
Industry Median: -143.325 vs XKRX:142760: 0.89

MOA Life Plus Co FCF Margin % Historical Data

The historical data trend for MOA Life Plus Co's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MOA Life Plus Co FCF Margin % Chart

MOA Life Plus Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-35.41

-29.03

-7.15

-101.81

31.77

MOA Life Plus Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
FCF Margin %	Get a 7-Day Free Trial															-5.26	4.08	2.13	-371.62	460.86

Competitive Comparison of MOA Life Plus Co's FCF Margin %

For the Biotechnology subindustry, MOA Life Plus Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MOA Life Plus Co's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MOA Life Plus Co's FCF Margin % distribution charts can be found below:

* The bar in red indicates where MOA Life Plus Co's FCF Margin % falls into.

MOA Life Plus Co FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

MOA Life Plus Co's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	5796.368	/	18245.316
	=	31.77 %

MOA Life Plus Co's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	18224.217	/	3954.432
	=	460.86 %

MOA Life Plus Co FCF Margin % Related Terms

Thank you for viewing the detailed overview of MOA Life Plus Co's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

MOA Life Plus Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MOA Life Plus Co Ltd (XKRX:142760) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

767, Sinsu-Ro, 7th Floor, Suji-gu, Gyeonggi-do, Yongin-Si, KOR, 305-500

Website

http://www.bioleaders.co.kr

BL Corp, formerly Bioleaders Corp engages in the biomedicine and biomaterial business in South Korea. It develops cervical intraepithelial dysplasia treatment which is in phase 3 clinical-stage; cervical cancer treatment which is in phase 2b clinical stage; and non-clinical vaccine adjuvant and treatment for muscular dystrophy.

MOA Life Plus Co Headlines

No Headlines